Pulmonary embolism (PE) occurs in 600,000 to 1 million individuals each year, and has a
15% 1-year mortality, making it the third leading cause of cardiovascular mortality in the …

Objectives Pulmonary embolism (PE) is associated with a substantial economic burden.
However evidence from patients in Europe is scarce. The aim of this study was to report the …

Pulmonary embolism (PE) is caused by a blockage of blood flow in a pulmonary artery, often
due to a clot traveling from a vein in a lower extremity [1, 2]. The annual worldwide incidence …

Background Although anticoagulation therapy can reduce the risk for pulmonary embolism
(PE) recurrence, symptoms such as exertional dyspnea or pain can persist for several …

Background To our knowledge, studies evaluating the quality of life (QoL) in patients with a
history of acute pulmonary embolism (PE) are not available, even though QoL is a key …

Funding: The project described in this publication was supported in part by University of
Rochester CTSA award No. KL2 TR001999 (to DL) from the National Center for Advancing …

Background Little data exist regarding the functional capacity of patients following acute
pulmonary embolism. We sought to characterize the natural history of symptom burden, right …

Background In routine clinical practice, in most countries, patients with pulmonary embolism
(PE) are hospitalized for clinical surveillance and to start anticoagulant treatment. Clinical …

Background The functional capacity of long-term survivors of submassive pulmonary
embolism (PE) is unreported. A six-minute walk distance (6MWD)< 350 m and reduced heart …

Objective To address the association between psychiatric disorders and short-term
outcomes after acute symptomatic pulmonary embolism (PE). Methods We identified adults …